Rilvegostomig Plus Trastuzumab-Deruxtecan for Early-Stage Breast Cancer: The I-SPY2.2 Randomized Clinical Trial.
Author / Organization: I-SPY2 Trial Investigators and Advocates, O'Sullivan CC, Kalinsky KM, Yau C, Kulkarni T, Yee D, Wallace AM, Chien AJ, Boughey JC, Elias AD, Nanda R, Isaacs C, Omene C, Stringer-Reasor E, Clark AS, Thomas A, Han HS, Chan N, Williams N, Trivedi MS, Arora M, Vaklavas C, Tseng J, Bommakanti S, Anampa Mesias JD, Zimmer A, Falkson C, Torres ER, Nangia C, Albain KS, Rozenblit M, Zare S, Fazelli S, Chen YY, Huppert LA, Church AL, Beckwith H, Carroll E, Solanki M, Borges VF, Tevis SEA, Chen N, Zeck JC, Kowzun MJ, Sullivan J, Marshall N, Klein ME, Giridhar KV, Acharya-Leon R, Fan B, Walsh EM, Litvak A, Jahan N, McDonald E, Douglas EH, Zena J, Guth A, Johnson K, McGuinness JE, Matsuda K, Shakeri S, Krishnamurthy J, Kang I, Madans A, Feldman S, Johnson M, Katerji H, Ma Y, Matthews JB, Delson AL, LeStage B, Perlmutter J, Petricoin EF, Shatsky RA, Price E, Basu A, Asare AL, Helsten T, McNatt MH, Mukhtar RA, Symmans WF, Borowsky AD, Heshman DL, DeMichele AM, Rugo HS, Hylton NM, van 't Veer LJ, Esserman LJ
| File Format | PDF (Portable Document Format) |
|---|---|
| Publication Year | 2026 |
| Source Host |
PubMed Central
(pmc.ncbi.nlm.nih.gov)
|
| License / Terms | Open Access / Creative Commons |
Ready for Immediate Access
Your selected document is ready for instant access with zero mandatory waiting period.